With $1 trillion on the line in NIH grants, the question is not whether discrimination affects health. It is how much we still need to learn about the pathways, costs and policy implications.

A canceled NIH grant can look like a narrow administrative story. It is not. It is a reminder that the study of discrimination and health sits at the intersection of public health, economics and public trust. When researchers examine how discrimination shapes health, they are not making a symbolic argument. They are trying to understand a real-world mechanism that can affect bodies, behavior and budgets.

Nancy Krieger, a researcher who was among the first to have her grants canceled in the recent wave of DOGE-related cuts, said the grant cancellation came as a shock and raised broader concerns about the future of research into racial health inequities. She is now among the scientists speaking out about a proposal that would rewrite federal grant rules in a way that could expand political appointee control over nearly $1 trillion in funding and make the recent turmoil in science grants a permanent feature of the system, rather than just a temporary bug.

The evidence base for work like Krieger’s — in which she was studying how discrimination, racism and other social and structural conditions shape health disparities with a particular focus on the pathways linking those forces to unequal health outcomes — is strong enough that the basic question is no longer whether discrimination matters. Reviews published in the past few years show that racial discrimination is associated with a wide range of adverse outcomes, including depression, anxiety and other physical and mental health harms. A 2023 critical review also links race, implicit bias and structural racism to social determinants of health, health care quality and health outcomes.

That matters because the consequences rarely stop at the bedside. If discrimination contributes to chronic stress, delayed care, poorer outcomes or reduced trust in institutions, those effects can ripple outward into higher medical spending, lower productivity and broader economic losses. In that sense, discrimination is not only a moral issue. It is also an economic one.

Researchers study this topic because they are trying to trace the mechanisms that connect experience to outcome. Chronic stress can affect sleep, blood pressure, immune response and mental health. Discriminatory treatment can also influence whether people seek care, whether they trust providers and whether they follow through on treatment. A 2024 overview of discrimination in health care notes that inequitable treatment persists and that lower-quality care for marginalized groups remains a serious problem.

That is why the cancellation of a study in this area deserves attention even if one avoids weighing in on the funding decision itself. The larger issue is what gets lost when the research stops. Canceling a grant does not cancel the problem it was designed to study. It simply leaves policymakers, employers, health systems and communities with less evidence about how discrimination operates and what interventions might actually work.

The stakes are even higher when the cuts affect who gets to take part in the science. Recent reporting and research on NIH grant terminations suggest that health equity work has been hit especially hard and that scientists from historically underrepresented groups have borne a disproportionate share of the damage. That matters because it shapes which questions are asked, which communities are centered and which problems remain underexamined.

The Jackson Heart Study conducted in my hometown of Jackson, Miss., is a useful reminder of what sustained research into issues plaguing underserved communities can do. The study has produced important insights into Black heart health and, just as important, it had to build trust in the community before it could generate that evidence. That is how public health research works at its best. It identifies a problem, earns trust, collects data and helps design interventions that can improve outcomes over time.

That is the bigger question behind canceling grants that study discrimination and discrepancies in health. Who decides which scientific questions are worthy of investment? And what happens when those questions are the ones most connected to unequal health outcomes? The answer is not abstract. It affects what we know about disease, what we spend to treat it and whether interventions are designed with the people most affected in mind.

Studying discrimination and health is not about turning every inequity into a slogan. It is about understanding preventable harm before it becomes more expensive, more entrenched and more deadly. The evidence says this is a legitimate and necessary area of public health research. The real cost of canceling it is not just the loss of one grant. It is the loss of knowledge that communities, employers and policymakers need in order to act wisely.